Site Survey
Free Courses
Skip links

CytoSorbents’ Product Associated With High Survival In Critically Ill COVID-19


  • CytoSorbents Corporation (NASDAQ:CTSO) has announced topline results from its CytoSorb Therapy in COVID-19 (CTC) multicenter registry.
  • The data were presented at the International Symposium on Intensive Care and Emergency Medicine.
  • The CTC Registry included 52 consecutive critically ill COVID-19 patients with refractory acute respiratory distress syndrome (ARDS) on life support with ECMO and CytoSorb.
  • The primary outcome of 90-day ICU mortality was 27% in the CTC Registry, below the 50% in the North American cohort of the international Extracorporeal Life Support Organization (ELSO) Registry in over 4,600 patients.
  • Rates of ICU discharge and recovery exceeded ICU mortality rates throughout the follow-up period. All patients discharged alive from the ICU also survived to hospital discharge.
  • CytoSorb treatment led to a decrease in elevated baseline inflammatory biomarkers.
  • Also Read: CytoSorbents’ Antithrombotic Removal System Scores Second FDA Breakthrough Device Tag.
  • Price Action: CTSO shares are up 4.08% at $9.96 during the premarket session on the last check Wednesday.

“; if (news== null || news.length < 1) { tableString += "No news available.”; } else { for (var i = 0; i < news.length; i++) { tableString += "“; for (var j = 0; j < news[i].Cells.length; j++) { var currentCell = news[i].Cells[j]; var cellCssClass = currentCell.CssClass; if (cellCssClass == null || cellCssClass.toString() == "") { tableString += "“; } else { tableString += ““; } for (var k = 0; k < news[i].Cells[j].Content.length; k++) { var currentContent = news[i].Cells[j].Content[k]; var contentCssClass = currentContent.CssClass; if (contentCssClass == null || contentCssClass.toString() == "") { tableString += currentContent.Value; } else { tableString += "" + currentContent.Value + "]]>

“; } } tableString += “”; } tableString += “”; } } tableString += “”; $(‘#detail-news-table’).html(tableString); try { trackPI(); } catch (e) { } }; function insertNewsHelp() { var help = “To give you an overview of the large number of messages that appear every day for a company, we have broken the news feed in the following categories:u003cbr/u003eRelevant : News from selected sources that deal specifically with this company u003cbr/u003eAll: All news about this company. u003cbr/u003eCompany News: News issued by the company directly.”; $(‘#detail-news-table’).html(help); try { trackPI(); } catch (e) { } };

Source

Leave a comment

X